Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18- 80 years of age, both sexes, all races and ethnic groups.~* Diagnosis of restless legs syndrome~* Disease duration longer than 3 months~* Restless Leg Syndrom Rating Scale score of 11 or above (moderate and above)~* Subjects who are eligible to be treated with a botulinum toxin for a therapeutic reason based upon the physicians' clinical experience.~* Subjects who are able to read, speak, and understand English.~Exclusion Criteria:~* Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders).~* Pregnancy or planned pregnancy (determined by urine pregnancy test). Women of childbearing age should use a reliable mode of contraception during the study period (abstinence, etc).~* Active breast feeding.~* Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.~* Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication.~* Subjects who are younger than 18 years of age.~* Neuromuscular-junction disorders.~* Evidence of acute pathology by neuro-imaging.~* Axis I diagnosis determined by a neurologist or psychiatrist.~* Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.~* Subject has received botulinum toxin injections in the past 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo , saline (Type: PLACEBO_COMPARATOR): The subject may be randomly assigned to receive Placebo, saline
- IncobotulinumtoxinA Treatment (Type: ACTIVE_COMPARATOR): The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)

Based on this trial design, predict the completion outcome and termination type (if applicable).